MTOR and breast cancer: The potent inhibitor pyrrophenone13 (5, Fig. 1) has been used in various in vitro and in vivo studies, while RSC-3388 (6, Fig. 1) has been shown to sensitize aggressive breast cancer to doxorubicin through suppressing ERK and mTOR kinases14, and to halt Streptococcus pneumonia-induced polymorphonuclear cells transepithelial migration in vitro, highlighting the importance of cPLA2α in eliciting pulmonary inflammation during pneumococcal infection15.